Drugs /

mrna-4157

Back to Drugs List

Overview

NCI Definition [1]:
An mRNA-based individualized, therapeutic personalized cancer vaccine (PCV) targeting twenty tumor-associated antigens (TAAs) that are specifically expressed by the patient's cancer cells, with potential immunostimulatory and antineoplastic activities. The cells from the patient's tumor are analyzed, and genetic sequencing is used to identify twenty neoantigen epitopes that may elicit the strongest immune response in the patient. The sequences encoding the twenty patient-specific epitopes are transcribed and loaded onto a single mRNA molecule. Upon administration, the mRNA-based PCV mRNA-4157 is taken up and translated by antigen presenting cells (APCs). Then, the expressed epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy the patient's cancer cells that express these neoantigens.

Clinical Trials

View Clinical Trials for mrna-4157

Mrna-4157 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating mrna-4157, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).

Deficient DNA Mismatch Repair (dMMR), HPV Negative, and MLH1 Deficient Expression are the most frequent biomarker inclusion criteria for mrna-4157 clinical trials.

Bladder urothelial carcinoma, colorectal carcinoma, and cutaneous melanoma are the most common diseases being investigated in mrna-4157 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mrna-4157
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mrna-4157 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
pcv mrna-4157, mrna-based pcv mrna-4157, mrna 4157, mrna-based personalized cancer vaccine mrna-4157
NCIT ID [1]:
C146813

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.